Immediate Impact
60 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Breast cancer: pathogenesis and treatments
2025 Standout
Works of Christina Arce being referenced
Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
2022
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2021 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Christina Arce | 274 | 224 | 117 | 144 | 18 | 556 | |
| Ram Chillar | 56 | 174 | 68 | 169 | 17 | 582 | |
| J Nectoux | 175 | 112 | 64 | 70 | 12 | 565 | |
| Toshiyuki Fukuhara | 186 | 88 | 34 | 53 | 27 | 568 | |
| Rashpal Flora | 179 | 172 | 43 | 51 | 17 | 459 | |
| B. G. Leventhal | 89 | 158 | 13 | 110 | 12 | 591 | |
| G.A. Edelstyn | 117 | 221 | 53 | 40 | 27 | 475 | |
| Gerardo Vergara | 196 | 172 | 74 | 133 | 18 | 502 | |
| Paraskevi Roussou | 73 | 137 | 28 | 100 | 21 | 521 | |
| Hae Su Kim | 170 | 262 | 90 | 144 | 25 | 497 | |
| Martin K. Hunn | 33 | 168 | 49 | 86 | 21 | 535 |
All Works
Loading papers...